NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

AMLX

Amylyx Pharmaceuticals Inc

Apr 17 • 04:00PM ET

3.98

Dollar change +0.16
Percentage change 4.19	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX BMRN ALNY SRPT NBIX ACAD SAGE RARE CYTK

| Held by: VTI VXF IBB SCHA SMLF VHT IWC AVSC SBIO PRFZ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.43	Insider Own	27.92%	Shs Outstand	68.63M	Perf Week	14.04%
Market Cap	352.64M	Forward P/E	-	EPS next Y	-1.52	Insider Trans	-0.52%	Shs Float	63.86M	Perf Month	9.04%
Income	-301.74M	PEG	-	EPS next Q	-0.49	Inst Own	56.46%	Short Float	5.91%	Perf Quarter	13.71%
Sales	87.37M	P/S	4.04	EPS this Y	57.52%	Inst Trans	24.82%	Short Ratio	4.56	Perf Half Y	1.02%
Book/sh	2.40	P/B	1.66	EPS next Y	19.02%	ROA	-84.87%	Short Interest	3.78M	Perf Year	98.01%
Cash/sh	1.99	P/C	2.00	EPS next 5Y	27.87%	ROE	-100.88%	52W Range	1.58 - 7.27	Perf YTD	5.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-78.71%	ROI	-182.62%	52W High	-45.25%	Beta	-0.55
Dividend TTM	-	Quick Ratio	6.67	Sales past 5Y	1825.06%	Gross Margin	-43.68%	52W Low	152.70%	ATR (14)	0.31
Dividend Ex-Date	Mar 28, 2018	Current Ratio	6.67	EPS Y/Y TTM	-705.82%	Oper. Margin	-292.63%	RSI (14)	59.35	Volatility	6.91% 8.60%
Employees	123	Debt/Eq	0.01	Sales Y/Y TTM	-77.06%	Profit Margin	-345.36%	Recom	1.83	Target Price	8.80
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-900.29%	Payout	-	Rel Volume	0.88	Prev Close	3.82
Sales Surprise	-	EPS Surprise	-5.77%	Sales Q/Q	-100.61%	Earnings	Mar 04 BMO	Avg Volume	827.65K	Price	3.98
SMA20	8.85%	SMA50	11.61%	SMA200	13.12%	Trades		Volume	724,313	Change	4.19%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-07-25	Upgrade	Mizuho	Neutral → Outperform	$7
Nov-18-24	Upgrade	Robert W. Baird	Neutral → Outperform	$3 → $11
Oct-23-24	Upgrade	BofA Securities	Neutral → Buy	$4.20 → $10
Mar-18-24	Downgrade	Mizuho	Buy → Neutral	$32 → $4
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral	$37 → $4
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27 → $4
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Jan-03-24	Initiated	Robert W. Baird	Outperform	$37
Dec-12-23	Initiated	Deutsche Bank	Buy	$36
Jul-24-23	Upgrade	Goldman	Neutral → Buy	$45 → $49
Mar-31-23	Initiated	Mizuho	Buy	$52
Jan-05-23	Initiated	BofA Securities	Buy	$50
May-25-22	Initiated	Citigroup	Buy	$21
Apr-01-22	Downgrade	Goldman	Buy → Neutral	$36 → $10

Show Previous Ratings

Apr-16-25 11:22AM	Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-11-25 08:11AM	Amgen says Imdelltra extended survival; Parker Institute adds new leaders (BioPharma Dive)
Apr-10-25 07:03AM	First subject dosed in Amylyxs Phase I trial of ALS therapy (Clinical Trials Arena)
Apr-09-25 07:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis (Business Wire) +5.44%
Apr-02-25 09:00AM	Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) +13.17%
10:17AM	Loading…
Mar-27-25 10:17AM	Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-05-25 10:01AM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +11.63%
Mar-04-25 06:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Mar-03-25 07:18AM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) -8.54%
Feb-25-25 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences (Business Wire)
Feb-24-25 09:00AM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 (Business Wire) -9.09%
Feb-10-25 09:00AM	Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-31-25 12:00PM	Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive)
Jan-21-25 09:00AM	Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (Business Wire)
08:26AM	Loading…
Jan-10-25 08:26AM	Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire) -7.16%
Jan-09-25 07:30PM	Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-06-25 09:00AM	Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer (Business Wire) -5.54%
Dec-30-24 02:52PM	Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-05-24 07:35AM	Amylyx announces design of LUCIDITY clinical trial (TipRanks) -5.51%
Dec-04-24 07:30AM	Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia (Business Wire)
Nov-27-24 09:00AM	Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire) +5.32%
Nov-08-24 02:11AM	Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
01:33AM	Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-24 07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results (Business Wire) +5.14%
Nov-04-24 09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-25-24 09:05PM	Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc (GuruFocus.com) +8.37%
Oct-19-24 11:12AM	Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments (Insider Monkey)
Oct-18-24 07:34AM	Amylyxs AMX0035 shows promise in Phase II Wolfram syndrome trial (Clinical Trials Arena) +21.94%
07:26AM	Why Amylyx Pharmaceuticals Stock Was So Healthy This Week (Motley Fool)
07:04AM	Loading…
07:04AM	PTC rebuffed again by EMA; Novartis licenses China-based biotechs cancer drug (BioPharma Dive)
Oct-17-24 09:00AM	Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome (Business Wire)
Oct-15-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 (Business Wire) +10.06%
Oct-09-24 05:32PM	Amylyx Pharmaceuticals Inc (AMLX) Q2 2024 Earnings Call Highlights: Strategic Pipeline ... (GuruFocus.com)
Sep-09-24 07:17PM	Director Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +6.33% +5.56%
Sep-06-24 01:49AM	Director MILNE GEORGE M JR Acquires 100,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +7.73%
Aug-28-24 08:30AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-24 09:00AM	Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration (Business Wire)
Aug-08-24 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-05-24 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
04:32AM	EC grants orphan drug status for Amylyxs Wolfram treatment (Pharmaceutical Technology)
Aug-02-24 09:00AM	Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Jul-10-24 10:53AM	Amylyx to rebuild pipeline with $35m Phase III ready GLP-1RA acquisition (Clinical Trials Arena) +25.45%
07:00AM	Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation (Business Wire)
03:00AM	Amylyx, with GLP-1 buy, doubles down on blood sugar drugs (BioPharma Dive)
Jul-09-24 04:01PM	Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide (Business Wire)
Jun-28-24 11:02AM	Amylyx ventures into metabolic diseases market with $35.1m deal (Pharmaceutical Technology)
Jun-04-24 09:00AM	Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-14-24 07:25AM	Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating (MT Newswires)
May-10-24 03:54PM	Amylyx Pharmaceuticals Reports Q1 2024 Financial Results (GuruFocus.com) -7.14%
12:47PM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results (Business Wire)
May-08-24 09:00AM	Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference (Business Wire)
May-02-24 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire)
Apr-30-24 12:02PM	Trials to watch: Four ALS drugs to keep an eye on (Clinical Trials Arena)
Apr-10-24 03:14PM	Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder (Benzinga) -7.87%
09:00AM	Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome (Business Wire)
Apr-08-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024 (Business Wire)
Apr-04-24 01:20PM	Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70% (Zacks)
10:05AM	ALS drug will be pulled from US market after study showed patients didn't benefit (Associated Press Finance)
07:52AM	UPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada markets (Reuters)
07:43AM	Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market (Barrons.com)
07:07AM	Amylyx Pharmaceuticals to remove ALS drug from US, Canada markets (Reuters)
07:00AM	Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO/ALBRIOZA from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy (Business Wire)
06:09AM	Amylyx to pull ALS drug from market in rare move (BioPharma Dive)
Apr-03-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire)
Apr-01-24 07:30PM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
Mar-27-24 07:36AM	European study finds popular ALS drug ineffective (BioPharma Dive) +5.11%
Mar-25-24 02:33PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire)
Mar-14-24 06:49PM	3 Pharma Stocks to Sell in March Before They Crash & Burn (InvestorPlace) -7.85%
09:00AM	Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors (Business Wire)
Mar-13-24 10:00AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx (PR Newswire)
09:03AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Mar-12-24 07:55AM	After surprise trial failure, ALS doctors brace for one less treatment option (BioPharma Dive) -9.47%
Mar-11-24 12:34PM	Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82% (Zacks) +13.10%
07:45AM	Amylyx CEOs look for a path forward following major setback (BioPharma Dive)
Mar-10-24 08:00AM	Wall Street Predicted a Blockbuster. Now the Drug May Be Withdrawn. (The Wall Street Journal)
Mar-08-24 06:27PM	Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations (Business Wire) -82.29% +13.10%
04:05PM	Amylyx Stock Wipes Out Nearly All Of Its Value, Crashing 82%, After Pivotal ALS Drug Failure (Investor's Business Daily)
11:30AM	Maker of much-debated ALS drug says it may stop selling it after study showed it didn't work (Associated Press Finance)
10:20AM	Amylyxs ALS Drug Fails Trial, Raising Questions About Companys Future (Barrons.com)
10:12AM	Amylyx Stock Crashes 80% After Approved ALS Drug Fails Its Pivotal Test (Investor's Business Daily)
09:38AM	10 Biotech Stocks with Huge Potential (Insider Monkey)
09:26AM	Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information (GlobeNewswire)
07:07AM	Amylyx's ALS drug fails in late-stage confirmatory study (Reuters)
07:00AM	Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS (Business Wire)
02:05AM	Amylyx ALS drug fails crucial study, putting companys future in doubt (BioPharma Dive)
Feb-27-24 05:45AM	Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX (PR Newswire) +8.20%
Feb-26-24 11:39AM	AMLX NEWS: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before the Lead Plaintiff Deadline (GlobeNewswire)
Feb-25-24 06:30AM	7 Oversold Russell 2000 Stocks to Add to Your February Buy List (InvestorPlace)
Feb-23-24 04:05PM	Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
10:30AM	AMYLYX SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options (GlobeNewswire)
10:10AM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	AMLX Stockholders with Significant Losses Should Contact Robbins LLP for Information About Their Rights and Remedies Against Amylyx Pharmaceuticals, Inc. (Business Wire)
05:45AM	Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AMLX (PR Newswire)
Feb-22-24 06:57PM	Investors Sue Amylyx Pharmaceuticals (AMLX) After Analyst Questions RELYVRIO Data Hagens Berman (GlobeNewswire) +21.10%
04:10PM	Amylyx Stock Rockets As ALS Drug Tacks On Another Triple-Digit Quarter (Investor's Business Daily)
08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates (Zacks)
07:35AM	Amylyx Pharmaceuticals Inc (AMLX) Reports Robust Revenue Growth and Net Income for Full Year 2023 (GuruFocus.com)

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FRATES JAMES M	Chief Financial Officer	Mar 31 '25	Sale	3.47	10,896	37,806	290,988	Apr 02 05:22 PM
Bedrosian Camille L	Chief Medical Officer	Mar 31 '25	Sale	3.47	12,425	43,082	194,375	Apr 02 05:14 PM
Mazzariello Gina	Chief Legal Officer	Mar 31 '25	Sale	3.48	9,192	31,954	187,969	Apr 02 05:12 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 31 '25	Sale	3.47	21,490	74,482	3,355,280	Apr 02 04:57 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 31 '25	Sale	3.46	21,490	74,454	3,355,276	Apr 02 04:52 PM
Zeiher Bernhardt G	Director	Mar 20 '25	Buy	3.70	10,000	37,005	10,000	Mar 24 04:15 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 03 '25	Sale	3.15	4,595	14,483	3,196,648	Mar 05 04:35 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 03 '25	Sale	3.17	4,595	14,549	3,196,652	Mar 05 04:32 PM
Mazzariello Gina	Chief Legal Officer	Mar 03 '25	Sale	3.12	1,611	5,022	133,310	Mar 05 04:32 PM
Mazzariello Gina	Chief Legal Officer	Feb 24 '25	Sale	3.15	4,169	13,145	134,921	Feb 26 04:35 PM
Klee Justin B.	Co-Chief Executive Officer	Feb 05 '25	Option Exercise	1.57	36,310	57,007	3,201,243	Feb 06 08:17 PM
Mazzariello Gina	Chief Legal Officer	Feb 03 '25	Sale	3.49	3,678	12,839	139,090	Feb 05 04:58 PM
Cohen Joshua B	Co-Chief Executive Officer	Feb 03 '25	Sale	3.47	11,851	41,108	3,201,247	Feb 05 04:55 PM
Klee Justin B.	Co-Chief Executive Officer	Feb 03 '25	Sale	3.47	11,855	41,104	3,164,933	Feb 05 04:54 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 06 '25	Sale	4.04	7,471	30,202	3,176,788	Jan 08 05:29 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 06 '25	Sale	4.05	7,471	30,232	3,213,098	Jan 08 05:26 PM
Bedrosian Camille L	Chief Medical Officer	Dec 02 '24	Sale	5.54	5,421	30,007	138,380	Dec 03 05:21 PM
Klee Justin B.	Co-Chief Executive Officer	Nov 04 '24	Option Exercise	1.57	63,690	99,993	3,184,259	Nov 06 07:24 PM
Klee Justin B.	Co-Chief Executive Officer	Sep 30 '24	Sale	3.20	18,589	59,429	3,120,569	Oct 02 06:53 PM
Cohen Joshua B	Co-Chief Executive Officer	Sep 30 '24	Sale	3.20	18,589	59,414	3,220,569	Oct 02 06:53 PM
Bedrosian Camille L	Chief Medical Officer	Sep 30 '24	Sale	3.20	11,442	36,559	143,801	Oct 02 06:50 PM
Mazzariello Gina	Chief Legal Officer	Sep 30 '24	Sale	3.20	8,709	27,840	142,768	Oct 02 06:48 PM
Cohen Joshua B	Co-Chief Executive Officer	Sep 23 '24	Option Exercise	1.57	1,857	2,915	3,239,158	Sep 25 05:56 PM
Cohen Joshua B	Co-Chief Executive Officer	Sep 12 '24	Option Exercise	1.57	34,449	54,085	3,237,301	Sep 16 05:39 PM
FRATES JAMES M	Chief Financial Officer	Sep 12 '24	Buy	2.53	40,000	101,368	233,464	Sep 16 05:30 PM
Firestone Karen	Director	Sep 05 '24	Buy	2.13	50,000	106,590	55,000	Sep 09 04:05 PM
MILNE GEORGE M JR	Director	Sep 03 '24	Buy	2.20	100,000	219,800	858,571	Sep 05 07:26 PM
Quimi Daphne	Director	May 14 '24	Buy	1.89	2,750	5,184	2,750	May 16 07:37 PM
Quimi Daphne	Director	May 15 '24	Buy	1.89	2,250	4,252	5,000	May 16 07:37 PM
Mazzariello Gina	Chief Legal Officer	May 15 '24	Sale	1.88	10,455	19,654	151,477	May 16 07:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMLX

Amylyx Pharmaceuticals Inc

Upgrade your FINVIZ experience